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Targeted proteomics via selected reaction monitoring (SRM) or parallel reaction 
monitoring (PRM) enables fast and sensitive detection of a preselected set of target 
peptides. However, the number of peptides that can be monitored in conventional 
targeting methods is usually rather small. Recently, a series of methods has been 
described that employ intelligent acquisition strategies to increase the efficiency of mass 
spectrometers to detect target peptides. These methods are based on one of two 
strategies. First, retention time adjustment-based methods enable intelligent scheduling 
of target peptide retention times. These include Picky, iRT, as well as spike-in free real 
time adjustment methods like MaxQuant.Live. Second, in spike-in triggered acquisition 
methods like SureQuant, Pseudo-PRM, TOMAHAQ and Scout-MRM, targeted scans 
are initiated by abundant labeled synthetic peptides added to samples before the run. 
Both strategies enable the mass spectrometer to better focus data acquisition time on 
target peptides. This either enables more sensitive detection or a higher number of 
targets per run. Here, we provide an overview of available advanced targeting methods 
and highlight their intrinsic strengths and weaknesses and compatibility with specific 
experimental setups. Our goal is to provide a basic introduction to advanced targeting 











 In mass spectrometry (MS)-based proteomics, data acquisition strategies can be 
broadly characterized as discovery or targeted approaches. Discovery approaches like 
data-dependent acquisition (DDA) and data-independent acquisition (DIA) aim to 
maximize the number of peptide identifications/quantifications per measurement time (1, 
2). Since DDA and DIA are biased towards detection of more abundant peptides, both 
of these discovery approaches have drawbacks when it comes to the reproducible 
identification and quantification of specific low abundance peptides. As many peptides 
of special interest are often of low abundance (such as peptides derived from proteins 
thought to be particularly “relevant” like kinases, transcription factors, or specific post-
translationally modified peptides), this limits the broad application of discovery methods 
in high-throughput basic research or clinical set-ups (3–10). 
Targeted approaches like selected reaction monitoring (SRM, also known as 
multiple reaction monitoring or MRM) (11, 12) and parallel reaction monitoring (PRM) 
(13, 14) enable highly sensitive, reproducible, and fast detection and accurate 
quantification of predefined sets of target peptides. For detailed information on these 
technologies we refer the reader to excellent reviews (15–17). Briefly, during a standard 
SRM or PRM run, the mass spectrometer continuously acquires spectra at the expected 
mass to charge (m/z) ratio and chromatographic retention time (RT) of target peptides. 
SRM experiments are performed on triple quadrupole mass spectrometers where 
precursor ions are selected in the first quadrupole and fragmented in the second 
quadrupole. Target-specific fragment ions are then selected in the third quadrupole for 
detection. Typically, several fragment ions are successively monitored. Triple 
quadrupole mass spectrometers are robust and relatively cheap, contributing to 
implementation of SRM assays in a clinical setting (9, 18). In contrast to SRM, PRM 
experiments are performed on systems able to record whole fragment spectra such as 
Quadrupole-Orbitrap type mass spectrometers and QqTOF Systems. In PRM, all 
fragment ions of a selected precursor are measured in parallel. In conventional SRM or 
PRM set ups, an inclusion list is passed on to the mass spectrometer that dictates the 
precursor m/z ratio windows and RT windows. On specific systems more scan 










times. For SRM the inclusion list additionally specifies the m/z of the fragment ions to be 
monitored.  
The selection of the suitable target peptides and fragment ions as surrogates for 
the target proteins is essential to the sensitivity, specificity and analytical power of 
targeted assays (17, 19, 20). But this can be laborious and time consuming: Peptides 
need to be selected considering their proteotypicity and detectability (21) and for the 
fragment ions that are monitored in SRM assays, the analytical specificity (low signal 
interference) is very important. This can be a bottleneck for certain applications of 
conventional targeted methods due to the time-consuming nature of the evaluation and 
validation process (22). To facilitate this process, libraries with empirically determined 
peptide fragmentation spectra have been established (23, 24). Alternatively, 
fragmentation spectra can also be predicted in silico (25, 26). Resources such as the 
online database SRMAtlas (23), Skyline software (27) and others (28–30) assist in the 
design of targeted methods by facilitating access to online repositories of empirical data, 
enabling in silico prediction of spectra, or validation of transitions.  
Key advantages of targeted approaches over discovery approaches are that they 
allow highly specific and sensitive measurements (17). Specificity results from the two 
successive mass filtering steps -- one at the precursor ion (MS1) and one at the 
fragment ion (MS2) level, which greatly increases the signal to noise ratio. Sensitivity 
depends on the time the mass spectrometer spends on collecting target peptide ions, 
the so-called dwell time. During targeted acquisition, the mass spectrometer only needs 
to analyze target peptides and can ignore all others, which results in longer dwell times 
compared to discovery approaches. In SRM, the dwell time per transition can highly 
vary between and within setups. Ranges from 13 to 256 ms have been reported (31, 32) 
(Table 1). Typically, multiple transitions per peptide are monitored. In PRM, where the 
whole peptide spectrum is acquired at once, reported ion accumulation times vary from 
15 to 550 ms (Table 1). In combination, the high specificity and sensitivity of targeted 
methods allows analysis of peptides that escape detection in discovery experiments 
(12, 13).  
In addition, accurate (and potentially absolute) quantification can be achieved 










Monitoring both heavy and the light peptides can then be used to quantify the 
abundance of endogenous peptides relative to the SIL spike-in. Alternatively, 
quantification can also be done ‘label-free’ or by spiking in a labeled reference peptide 
(LRP) (35–37). SRM has early on been shown to reach a limit of detection (LOD) in the 
attomole range (17, 38), and PRM performs similarly in terms of sensitivity, dynamic 
range and quantitative accuracy (39, 40) (Table 1). In a recent publication, PRM 
reached a limit of quantification (LOQ) ranging from 4 amol to 103 amol depending on 
the target peptide (41).  
A major drawback of targeting approaches is the limited number of peptides that 
can be targeted in parallel: Typical PRM-based methods enable reliable detection and 
quantification of 10-100 target peptides (5) (Table 1), but when the number of target 
peptides increases the performance suffers. SRM methods have already quantified up 
to 100s of peptides in a single LC run (42) (Table 1). However, this requires optimized 
chromatographic conditions, and tedious selection of specific transitions. In recent 
years, a range of new tools and methods have been developed that use intelligent 
acquisition strategies to allow the mass spectrometer to better focus on the targeted 
peptides by intelligent scheduling strategies. In this review we discuss these advanced 
acquisition methods, and how they can improve the analytical performance and simplify 
targeted method design. 
In general, the number of peptides that can be targeted per run depends on 
several factors. First, since the mass spectrometer can only target a single peptide at 
any given time, the dwell times needed for sensitive detection determines the number of 
peptides that can be monitored in parallel. The limit of detection results from the 
interplay between the expected width of elution peaks, the number of points across the 
peak necessary for quantification (typically 8-15 points (43, 44)), the dwell time per 
peptide or transition, the number of peptides and transitions (for SRM) looked at in 
parallel, and the MS cycle time. Targeting too many peptides at the same RT results in 
long MS cycle times, which reduces the number of data points acquired across elution 
profiles and has detrimental consequences on quantification and reliability of detection. 











By scheduling targeted experiments, the number of target peptides can be 
increased. In contrast to unscheduled targeted experiments, where the same peptides 
are monitored throughout the entire run, in scheduled targeting experiments peptides 
are only targeted during a monitoring window around their expected RT. These 
monitoring windows are a second factor that limits the number of targets. To ensure 
reproducible detection, monitoring windows need to be wide enough to capture 
deviations from the expected elution time (Fig. 1 A, B). The windows are typically about 
5-10 times wider than actual chromatographic peak widths (depending on the gradient 
length, see table 1), which decreases the number of peptides that can be targeted per 
run.  
Several advanced acquisition methods have been developed in recent years that 
address these challenges by intelligent scheduling schemes. In general, these 
advanced targeting methods employ one of two strategies. The first strategy is retention 
time adjustment, which is a variation of conventional scheduled targeted acquisition. In 
these methods, the aim is to keep the targeting windows shorter by adjusting the 
expected retention time to achieve a more accurate estimation of the actual retention 
time (Fig. 1C). The second strategy does not make use of targeting windows, but 
instead uses synthetic spike-in reference peptides to directly trigger acquisition of 
endogenous target peptides (Fig. 1D).  
The available advanced acquisition methods are based on different ideas and 
have been established on different mass spectrometers. This makes it difficult to 
choose a method that is well-suited for a specific application. Also, we realized that 
many original papers describing advanced acquisition methods do not reference each 
other, which makes it difficult for new scientists in the field to get an overview of the 
methods currently available. Here, we provide a basic overview of currently available 
advanced acquisition methods for targeted runs. Rather than reviewing these methods 
in detail, we focus on their conceptual differences and highlight their inherent strengths 
and weaknesses. A summary of the methods discussed here is provided in Table 2, 











Retention time adjustment-based methods 
Retention time (RT) adjustment methods estimate the RTs of target peptides and 
adjust monitoring windows accordingly. More accurate estimation of peptide RTs means 
that monitoring windows can be kept shorter without missing peptides, thus enabling 
more target peptides per run (Fig. 1C). 
RTs are not universal constants for a given peptide but are affected by the 
specific chromatographic conditions employed (type, length and age of the column, 
buffer composition, LC gradient, flow rate etc). In a conventional scheduled targeting 
experiment, target peptide RTs for a specific setup are either predicted or determined 
empirically in measurements prior to the experiment. Prediction of retention time is 
either based on intrinsic peptide properties like hydrophobicity (45, 46), or on machine 
learning approaches (47, 48) deep learning (25, 49). To facilitate design of scheduled 
targeted experiments the prediction tools SSRCalc and Prosit are implemented in 
Skyline (27, 45, 46). However, the prediction of peptide RT is imperfect, and research 
on RT prediction for post-translationally modified peptides has been lacking (50). 
Empirically determining peptide RTs can be costly (when a peptide needs to be 
synthesized) and time consuming. In addition, even when RTs have been correctly 
determined or predicted, they still vary stochastically from run to run (due to variability in 
LC pump speed, sample pick-up volume, changes in background etc.). 
Retention time adjustment-based methods aim to improve the accuracy of 
prediction “offline” as well as “on-the-fly”. Static RT adjustment methods that employ 
indexed Retention Times (“offline” iRT-based methods) or Picky estimate RTs of target 
peptide “offline” (that is, before the targeted acquisition run) and can therefore adjust RT 
shifts that arise due to user-specific chromatographic conditions. Real-time adjustment 
methods use spike-in standards (“on-the-fly” iRT-based methods) or background 
peptides (spike-in free real-time adjustment) to adjust monitoring windows in real time 
(that is, during the targeted acquisition run). The latter approaches are therefore also 











Picky is an online tool that simplifies the design of PRM and SRM experiments 
and adjusts peptide RTs to a specific HPLC setup (51). To this end, the tool uses 
experimentally determined peptide RTs and fragmentation spectra from the 
ProteomeTools database (24). The main input from the user is simply a list of human (or 
mouse) proteins to be targeted. Based on this input, Picky selects corresponding high 
scoring target peptides from the ProteomeTools database together with their 
experimentally observed RTs and suitable collision energies. To adjust RTs to specific 
HPLC conditions, users can upload any list of peptides and RTs generated on their own 
chromatographic setup. Picky then uses this information to rescale RTs of target 
peptides to the user-specific HPLC conditions. This significantly reduces RT-shifts 
based on LC-characteristics, thus enabling narrow monitoring windows. The tool 
exports optimized PRM/SRM acquisition methods in formats compatible with different 
mass spectrometers. Picky also exports a spectral library of target peptides that are 
useful for validation of the PRM/SRM data obtained. The main advantages of Picky are 
that it makes setting up optimized targeted acquisition methods easy and that the tool is 
compatible with different machines. A disadvantage is that the static retention time 
rescaling performed by Picky cannot capture run-to-run variability. 
 
Indexed retention times (iRTs) 
Indexed retention times (iRTs) are based on the idea to spike-in a standard set of 
reference peptides in order to normalize RTs of peptides in the sample (52). The iRT of 
a peptide is a dimensionless number representing the RT of a peptide relative to the 
reference peptides. By converting actual RTs to a reference-based index, RTs can be 
adjusted to different chromatographic set-ups. Similar to Picky, this can be used to 
transfer static RT estimates across labs and methods (“offline” iRT-based methods). A 
major advantage of the iRT concept is that it is widely integrated into publicly available 
databases and tools like ProteomeTools (24), SRMatlas (23) and Prosit (25). Also, 
Skyline facilitates the setup of scheduled targeted run design using peptide iRT values 











 In addition, iRTs can also be used to estimate target peptide RTs ‘on-the-fly’ 
(real-time adjustment of expected RTs) via dynamic RT window correction on some 
mass spectrometers (for example, over the dynamic Retention Time feature on Thermo 
HF-X instruments (55, 56)). The real time adjustment of RTs reduces run-to-run 
variability. The on-the-fly adjustment of target windows was first shown using a mixture 
of 150 synthetic isotopically labeled peptides (57). While any custom set of standard 
reference peptides can be used to define an iRT scale, the “iRT kit” from Biognosys, the 
“Peptide Retention Time Calibration Mixture” from Pierce and “PROCAL” from JPT (58) 
are three commercially available options.  
 
Spike-in free real-time adjustment 
While iRTs require spiking-in synthetic reference peptides, other methods 
take advantage of endogenous background peptides to estimate RTs of target 
peptides in real-time. MaxQuant.Live is a software framework for real-time monitoring 
of mass spectrometric data and controlling data acquisition (59). One of the applications 
implemented in this framework is “global targeting”, which leverages 10,000 easily 
recognizable peptides from a reference run to continuously minimize the median 
differences between the observed and the expected RTs. This adaptive nonlinear RT 
adjustment shrinked monitoring windows to less than one minute and enabled 
recognition and targeting of more than 25,000 peptides in single LC-MS runs. The 
MaxQuant.Live framework is flexible and allows users to define target peptide-specific 
dwell times, sequential isolation of light and heavy peptides or co-fragmentation of light 
and heavy peptides together. The software is freely available and compatible with 
Thermo Orbitrap mass spectrometers (tune version 2.9 or higher). 
Where the Maxquant.Live approach uses MS1 scans to monitor RT shifts, an 
alternative real-time chromatographic alignment approach from the MacCoss lab uses 
MS2 survey scans instead (60). To this end, the mass spectrometer periodically 
acquires DIA MS2 survey scans. These MS2 scans are aligned to a reference DIA 
experiment in real time in order to determine the RT shift and to adjust the active target 
list accordingly. With this strategy, the authors were able to reduce the peptide 










the MS2 rather than at the MS1 level increased robustness and selectivity of the RT 
alignment. The alignment was shown to be rather robust against changes in 
background abundance by performing dilution experiments.The method was 
implemented on a modified Fusion Lumos and is not yet freely available.  
Key advantages of spike-in free real-time acquisition methods are that they do 
not require spike-in peptides, and the high number of datapoints leveraged by the 
algorithms facilitate highly precise estimates of target peptides RT. These methods can 
take full advantage of the data while it is still being acquired by using complex data 
dependent decision trees. However, these methods are rather complex and depend on 
sufficient overlap in identified peptides between the measured sample and the reference 
library.  
 
Spike-in-triggered acquisition methods 
 The methods listed in the previous section aim to improve the precision of RT 
estimates, thereby enabling narrower targeting windows. The targeting windows, 
however, will most likely still exceed the elution peak of the target peptides, thereby 
reducing the number of targets per run. Methods based on spike-in-triggered acquisition 
circumvent peptide RT estimation and targeting windows all together. Instead of 
acquiring data at specific (adjusted) predefined RTs, the acquisition is initiated by the 
detection of trigger peptides. To this end, a synthetic heavy stable isotope labeled (SIL) 
peptide is added to the sample for every endogenous target peptide. During spike-in-
triggered acquisition, the mass spectrometer switches between two types of scanning 
modes: a “watch" mode and a “quantification" mode. In the watch mode, the mass 
spectrometer scans for the MS1 signal of the heavy spike-in trigger peptide. Since this 
SIL peptide is chemically identical to the endogenous (that is, light) peptide, the spiked-
in and the endogenous peptide have almost (note that deuterated peptides can show a 
significant RT shift) identical elution profiles. Therefore, the presence of the trigger 
peptide reliably indicates the RT at which the targeted peptide is also eluting, even in 
case its abundance is too low to be directly detected in watch mode. Detection of the 
trigger peptide then initiates the quantification mode that involves sensitive scanning for 










on the specific implementation of the method, quantitative scans per target may take up 
to 5s.  
Spike-in-triggered acquisition was originally published as “index-ion Triggered 
MS2 Ion Quantification” (iMSTIQ) (61) or “Internal Standard Triggered-Parallel Reaction 
Monitoring” (IS-PRM) (62) and has been further developed since then. Current 
implementations of this concept mainly differ in the specific acquisition algorithms 
employed by the mass spectrometer. For example, a potential problem of spike-in-
triggered acquisition is that MS1 background peaks with m/z ratios corresponding to 
trigger peptides can erroneously initiate the quantification mode, which leads to loss of 
valuable measurement time. In two of the methods mentioned below (SureQuant and 
TOMAHAQ), the quantification scans are only triggered after an MS2-level ‘spectrum 
check’ of the trigger peptide as an additional filter to enhance selectivity. 
Spike-in-triggered acquisition methods have the advantage that the presence of 
the trigger peptides precisely show where the endogenous target peptides are expected 
to be found, facilitating their detection. In addition, SIL trigger peptides can serve as a 
reliable internal reference for relative (and potentially absolute) quantification. The main 
disadvantage of these methods is that selecting, producing and validating suitable 
trigger peptides is time consuming and costly. 
 
SureQuant and related technologies 
 SureQuant was developed by Thermo and is pre-installed on the Orbitrap 
Exploris 480 and Orbitrap Eclipse tribrid systems. In a SureQuant run, detection of 
spiked-in SIL peptides over a pre-defined intensity threshold prompts a fast low-
resolution MS2 scan of the trigger peptides. The presence of trigger peptides is then 
confirmed via pseudo-spectral matching against pre-selected product ions. A positive 
match initiates a highly sensitive quantitative scan for the target peptide. The dwell time 
can be set individually for each target peptide. In addition to serving as a trigger, the 
spiked-in SIL peptides can also be used as a reference for precise quantification by 
monitoring both the heavy spiked-in and light endogenous peptides throughout their 
elution period. For example, similar to SRM methods (63, 64),  a recent paper described 










cancer tumors (65). 91% of the SIL and 78% of the endogenous phosphopeptides could 
be detected. While this study required synthesis of a custom set of SIL trigger peptides, 
assay kits for certain pathways or protein sets (AKT/mTOR pathway, PQ500 for 
serum/plasma) are commercially available.  
SureQuant requires specific algorithms in the acquisition software that are 
currently only available on the specific newer Thermo instruments. For other Orbitrap-
type instruments, Pseudo-PRM might provide an alternative means of implementing 
spike-in triggered acquisition (66). The method utilizes the offset fragmentation options 
in the acquisition software. The mass spectrometer operates in DDA mode with SIL-
trigger peptides added to an inclusion list. Detection of the trigger peptide in an MS1 
scan then initiates a targeted scan with a mass offset corresponding to the m/z ratio of 
the endogenous peptide, leading to continuous fragmentation of the target peptide. This 
simple acquisition method does not employ a ‘spectrum check’ to reduce erroneous 
triggering. Further benchmarking experiments to investigate the false positive rate in 
triggered scans would increase credibility of the method. 
 
TOMAHAQ 
TOMAHAQ (triggered-by-offset, multiplexed, accurate-mass, high-resolution, and 
absolute quantification) is a spike-in-triggered targeting method that takes advantage of 
isobaric labelling-based multiplexing (67, 68). The different samples to be compared 
with each other are labelled using tandem mass tags (TMT) (69) and combined. In 
parallel, synthetic trigger peptides are labelled with alternative TMT reagent termed 
TMTsh (TMT superheavy) that co-elutes with the corresponding target peptide at an 
offset m/z ratio. Detection of TMTsh synthetic trigger peptides sets off a series of scans 
to verify and identify the trigger peptide, identify the target peptide, optimize the 
quantification scan, and finally an optimized MS3 scan for target TMT reporter ions with 
dwell times as long as 5s. Quantification at the MS3 level is advantageous because it 
reduces co-isolation interference, which would otherwise impair TMT reporter ion-based 
quantification -- a pervasive problem especially in complex samples (70). TOMAHAQ 
enabled targeting of 520 peptides in unfractionated “single shot” samples, and the data 










Tomahto (67), the software to run TOMAHAQ acquisition methods, is freely 
available and compatible with Tribrid instruments. It only requires a list of peptide 
targets, which greatly simplifies setting up methods. The key advantage of 
TOMAHAQ/Tomahto is that TMT-based multiplexing greatly increases the number of 
samples that can be analyzed per unit time. Furthermore, the spectral match to confirm 
presence of the trigger peptide, as well as the long accumulation of TMT reporter ions (if 
necessary), make the method very sensitive. It is, however, more complex than 
SureQuant or Pseudo-PRM, and may also be affected by the TMT inherent 
quantification biases.     
 
Scout-MRM 
Instead of SIL peptides, Scout-MRM is based on so-called “scout” peptides to 
trigger targeted acquisition (71, 72). These scout peptides are designed to span the 
entire RT range and do not correspond to target peptides. To set-up targeted 
acquisition, target peptides are associated with one or several scout peptides that have 
similar retention times. During targeted acquisition, the detection of scout peptides 
triggers complex acquisition schemes for all associated target peptides. An advantage 
of this method is that trigger peptides are universal and do not need to be obtained for 
each target. However, since scout peptides do not have the same amino acid 
sequences as target peptides, they are less reliable than spiked-in SIL peptides for 
detection and quantification. Scout-MRM is currently only available on Sciex 
instruments. The recently released Peptide selector (72) tool simplifies the design of 
Scout-MRM methods.  
 
Conclusions 
Advanced targeted proteomics methods are emerging as attractive alternatives 
to untargeted DDA and DIA approaches. Smarter experimental designs and/or more 
advanced data acquisition algorithms enable sensitive detection of a higher number of 
targets per run. While computational proteomics so far mostly focused on the post 
acquisition analysis of mass spectrometric data, an emerging trend is to also use 










process using intelligent scheduling approaches allows users to better take advantage 
of the analytical power of the mass spectrometers employed. Also, these methods have 
been used to target entire signaling pathways and thus provide users with information 
about specific features they are interested in.  
The development and adaptation of the advanced acquisition methods would 
benefit from standardized technical benchmarking experiments that enable a 
comparison within the advanced acquisition methods themselves, and with the 
conventional targeted acquisition methods. For example, for the RT adjustment based 
methods, the accuracy of the retention-time prediction for different chromatographic set-
ups is relevant. For spike-in free RT adjustment methods, the robustness against 
variation in background should be shown. For the spike-in triggered acquisition 
methods, factors like reproducible triggering of the targeted scans, and the number of 
scans acquired across the LC peak with increasing numbers of targets would be 
interesting to compare between the advanced methods, but also with conventional 
methods. Additionally, validation procedures similar to the ones established for 
conventional targeting methods (34) support potential users in choosing the right 
strategy for the project. 
When should advanced acquisition proteomics method be used, and which 
method is the best fit? The answer to this question depends on a number of factors. 
First, the analytical challenge of the project is important: A simple targeting method, like 
PRM, can reproducibly detect a few rather abundant peptides, whereas monitoring 
hundreds of low abundance peptides is more challenging. SRM methods are sensitive 
and able to quantify a large number targets (Table 1), but selecting appropriate 
transitions is tedious and time consuming, making the assay hard to design or 
customize. For applications such as the quantification of signaling pathway activity, 
mapping of downstream biomarkers or cross-validation experiments to verify DDA and 
DIA results, the targets need to be quickly customizable and one of the advanced 
acquisition strategies might be a good fit. A second factor relates to the number of 
samples to be measured and the ease of implementing the methods: On the one hand, 
Picky is a simple tool that allows for quick customization of composition of target 










experiments and arguably preferable over western-blotting (73). On the other hand, 
methods like TOMAHAQ and SureQuant benefit from the improved run-to-run 
reproducibility, increased number of targets, sensitivity of spike-in-triggered acquisition 
and sample multiplexing (for TOMAHAQ). However, the need for custom trigger 
peptides makes these methods uneconomical for projects involving a small number of 
samples. iRT-based methods, spike-in free RT adjustment methods and Scout-MRM 
are somewhere in the middle between these two poles. A third and often decisive factor 
is simply the availability of a method on a certain mass spectrometer. For example, 
TOMAHAQ is only available on Thermo Tribrid instruments and Scout-MRM has only 
been implemented on Sciex machines. 
The ease of implementing these advanced targeted acquisition also depends on 
the availability of method design tools. Picky, TOMAHAQ and Scout-MRM come with 
software to select proteotypic peptides and plan their scheduled acquisition. To this end, 
Picky and Peptide selector (the tool associated with Scout-MRM) connect to the 
databases ProteomeTools (24) and SRMatlas (23), respectively. Peptide iRT values are 
also integrated in databases and in tools such as Skyline (27).  
In the future, we predict that targeted proteomics will assert itself as an attractive 
alternative to global DDA and DIA approaches. On the one hand, we expect that smart 
experimental designs in combination with sophisticated acquisition algorithms will be 
able to extract more and more useful information from samples in less and less time. 
This will also be supported by further improvements on the hardware side, such as 
increased MS scan rates, or using ion mobility for additional fractionation in the gas 
phase (74). Additionally, there are many other directions of improvements in the field of 
targeted proteomics that are outside the scope of this review. For example, the further 
expansion of online databases with empirical data such as PeptideAtlas (75), 
ProteomicsDB (24, 76) and Phosphopedia (77) for phosphopeptides can aid in the 
selection of detectable and specific proteotypic peptides and fragment ions. In a similar 
fashion, databases with targeted proteomic specific data like SRMatlas (23) and the 
CPTAC Assay Portal (78) can aid in the adoption of targeted methods. The continued 
development of tools that further simplify access to these databases (like Skyline or 










design of targeted methods. Other efforts have focussed on increasing sensitivity by 
improving sample preparation like enrichment or “offline” separation techniques (5, 38, 
79). Antibody based immuno-affinity enrichment or immuno-SRM focus on enrichment 
of target peptides using antibodies early before sample preparation. SISCAPA (Stable 
Isotope Standards and Capture by Anti-Peptide Antibodies) (80–82), combines antibody 
based enrichment with stable isotope labeled quantification. The target peptides and 
heavy labeled “counterparts” are captured by the antibodies simultaneously before MS 
analysis. Application of the method depends on the availability of antibodies (83). The 
method is widely applied, for example to study plasma (82), phospho-signalling (18, 84) 
and the biological activity of Thalidomide analogs (85). The combination of antibody 
based enrichment with advanced targeted acquisition methods would enable further 
improvement of the sensitivity of targeted proteomics.  
Furthermore, the continued improvements of  data-processing methods and 
tools, such as data analysis with Skyline and embedded tools (27, 86, 87) and 
Spectrodive, are especially important with increasing number of targets and large 
number of samples. Such developments will facilitate research by providing detailed 
functional information, like for example the activity of specific pathways (65, 67). On the 
other hand, less complex but more robust targeted acquisition approaches will likely 
become more relevant in clinical settings and could complement antibody-based 
detection for diagnosis and stratification (88–90). 
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Figure 1. Advanced targeted proteomics methods. Schematic elution profiles with 
target peptides (in red) are shown. Grey filled boxes depict monitoring windows in which 
continuous targeted scans are performed. (A) Elution profile of the reference run. RTs 
of target peptides are indicated. Elution profiles in B, C and D depict three different 
strategies to compensate for RT shifts (in this case delayed relative to the reference 
run). (B) Conventional targeting methods use wide monitoring windows (centered 
around expected elution time) to ensure that peptides are detected despite RT shifts. 
(C) RT prediction methods enable advanced targeting by better adjusting peptide RTs 
before (offline) or during (online) targeted acquisition. Blue ‘iRT’ peptides (or 
background peptides) are used to estimate shifts from predicted or previously observed 
RT, and shift the monitoring windows accordingly. This results in shorter monitoring 
windows. (D) Spike-in-triggered acquisition methods rely on synthetic spike-in peptides 
(grey). Detection of these peptides by the mass spectrometer triggers acquisition of 

















































- Advanced acquisition methods improve focus of mass spectrometers on 
target peptides 
- This review discusses existing methods based on two strategies 
- Retention time adjustment-based methods enable intelligent scheduling of 
peptide RTs 











The analytical power of targeted proteomics depends on how efficiently the mass 
spectrometer detects target peptides. A number of “smart” acquisition approaches have 
been developed that enable more targets per run and improve analytical performance 
like sensitivity, specificity and quantitative accuracy. This review provides an 











Table 1. Representative methods from literature. In publications where multiple methods were tested, representative methods were selected for the table. 
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Table 2. Technical overview of advanced targeting methods mentioned in review, with key analytic parameters of application 
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Retention time adjustment    Reference Realtime Application examples Specifics 
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40 min gradient 
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